Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Sponsor: TCR2 Therapeutics
Summary
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex and second, a PD-1:CD28 switch receptor, which is expressed on the surface of the T cell, independently from the TCR. The PD-1:CD28 switch receptor comprises the PD-1 extracellular domain fused to the CD28 intracellular domain via a transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.
Official title: A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2022-06-21
Completion Date
2028-10-30
Last Updated
2025-08-27
Healthy Volunteers
No
Conditions
Interventions
TC-510
TC-510
Fludarabine
Fludarabine
Cyclophosphamide
Cyclophosphamide
Locations (7)
University of California, San Francisco
San Francisco, California, United States
University of Miami
Miami, Florida, United States
National Cancer Institute
Bethesda, Maryland, United States
University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota, United States
Montefiore Einstein Cancer Center
The Bronx, New York, United States
University of Oklahoma
Oklahoma City, Oklahoma, United States
SCRI Oncology Partners
Nashville, Tennessee, United States